trans-methyl 4-(methylamino)cyclohexanecarboxylate hydrochloride | 146447-21-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: trans-methyl 4-(methylamino)cyclohexanecarboxylate hydrochloride
• 英文别名: methyl trans-4-(methylamino)cyclohexanecarboxylate hydrochloride
• CAS: 146447-21-4
• 化学式: C₉H₁₇NO₂*ClH
• 分子量: 207.7
• InChiKey: MNCVKHSSYUYIRI-KMMPGQJCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.36
• 重原子数：
  13.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  38.33
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  trans-methyl 4-(methylamino)cyclohexanecarboxylate hydrochloride 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 、 caesium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl (1r,4r)-4-{[2',6'-bis(benzyloxy)-[3,3'-bipyridin]-6-yl](methyl)amino}cyclohexane-1-carboxylate
  参考文献：
  名称：

  [EN] BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
  [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE PROGÉNITEUR HÉMATOPOÏÉTIQUE KINASE ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.

  公开号：

  WO2023086399A1
• 作为产物：
  描述：

  trans-methyl 4-((tert-butoxycarbonyl)(methyl)amino)cyclohexanecarboxylate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 以88%的产率得到trans-methyl 4-(methylamino)cyclohexanecarboxylate hydrochloride
  参考文献：
  名称：

  [EN] ATX MODULATING AGENTS
  [FR] AGENTS DE MODULATION D'ATX

  摘要：

  式(I)的化合物可以调节自体税肽酶（ATX）的活性。

  公开号：

  WO2015188051A1

文献信息

• [EN] 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS<br/>[FR] DÉRIVÉS DE 4-BENZYLAMINOPYRROLIDINE 1,2-DISUBSTITUÉE COMME INHIBITEURS DE CETP UTILES POUR LE TRAITEMENT DE MALADIES TELLES QUE L'HYPERLIPIDÉMIE OU L'ARTÉRIOSCLÉROSE
  申请人：NOVARTIS AG

  公开号：WO2009071509A1

  公开（公告）日：2009-06-11

  The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

  本发明提供了一种化合物，其化学式为（I）：其中变体R1、R2、R3、R4、R6、R7如本文所定义，并且所述化合物是CETP的抑制剂，因此可用于治疗由CETP介导的或对CETP抑制产生响应的疾病或疾病。
• Fused furan compound
  申请人：Kawaguchi Takayuki

  公开号：US20060094724A1

  公开（公告）日：2006-05-04

  The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R 3 is hydrogen or the like; and, R 4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.

  本发明提供了式(I)的紧凑呋喃化合物：其中环X是苯、吡啶或类似物；Y是可选取代的氨基、可选取代的环烷基、可选取代的芳基、可选取代的饱和杂环基、可选取代的不饱和杂环基；A是单键、低级烷基、低级烯基亚烷基、低级烯基亚烯基或氧原子；R3是氢或类似物；R4是氢或类似物，或其药学上可接受的盐，其用作药物，特别是作为激活的血凝血酶X抑制剂。
• Benzofuran derivative
  申请人：Kawaguchi Takayuki

  公开号：US20050282808A1

  公开（公告）日：2005-12-22

  The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: —N═ or —CH═; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R 1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R 3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.

  本发明提供了一种苯并呋喃衍生物，其化学式为[1]：其中x是公式：—N═或—CH═的基团；Y是可选取的取代氨基、可选取的取代环烷基或可选取的饱和杂环基团；A是单键、可选取的具有双键或位于链的末端的碳链或氧原子；R1是氢原子或卤素原子；环B是可选取的取代苯环；R3是氢原子或其药学上可接受的盐，该化合物作为药物特别是激活的血凝血因子X抑制剂。
• Aminoalkylamide substituted cyclohexyl derivatives
  申请人：Ackermann Jean

  公开号：US20050065210A1

  公开（公告）日：2005-03-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , U, V, W, k and m are as defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasit infections, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、R5、U、V、W、k和m在说明书和权利要求中定义，并且它们的药学上可接受的盐和/或药学上可接受的酯。该化合物可用于治疗和/或预防与2,3-氧化甾醇-鲨烯环化酶有关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌感染、寄生虫感染、胆结石、肿瘤和/或增生性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• Amide type carboxamide derivative
  申请人：Kawaguchi Takayuki

  公开号：US20060287329A1

  公开（公告）日：2006-12-21

  The present invention provides an amide-type carboxamide derivative of the formula [1]: wherein X is a group of the formula: —N═ or the formula: —CH═; R 1 is a halogen atom, a lower alkyl group, and the like; R 2 is a group of the formula: and the like; Y 1 and Y 2 are the same or different and each is a group selected from a halogen atom, a lower alkyl group, a lower alkoxy group, and the like; Ring A is phenyl group, and the like, or a pharmaceutically acceptable salt thereof, which is useful as an inhibitor of FXa.

  本发明提供了一种式[1]的酰胺型羧酰胺衍生物，其中X是式：—N═或式：—CH═的基团；R1是卤素原子、低烷基等；R2是式：及类似基团；Y1和Y2相同或不同，每个都是从卤素原子、低烷基、低烷氧基等中选择的基团；环A是苯基等，或其药学上可接受的盐，可用作FXa抑制剂。